Supplementary Material for: Targeted Ileal Bile Acid Transporter Inhibition as Rescue Ther

A single-patient case report from figshare details the use of elobixibat to treat severe constipation in a 56-year-old female with obesity during tirzepatide therapy. The 829.3 KB PDF document, authored by figshare admin karger and last updated on 2026-05-09, presents clinical observations including patient weight, BMI, medication dosages, and weekly stool frequency. It concludes that ileal bile acid transporter inhibition may be a mechanism-based rescue therapy.

Use Cases

• Analyzing the temporal relationship between tirzepatide dosing and constipation symptoms based on the weekly symptom timeline described.
• Studying the dose-response effect of elobixibat based on the reported changes from 10 mg to 5 mg daily.
• Evaluating treatment efficacy based on the reported improvement in weekly bowel movement frequency and Bristol Stool Chart types.
• Investigating patient-reported outcomes based on the resolution of perianal symptoms and defecation pain mentioned.

Strengths

• Detailed longitudinal clinical data for a single case, including specific medication dosages (tirzepatide 10 mg, elobixibat 10 mg/5 mg).
• Quantifies outcomes with specific metrics: patient weight (95 kg), BMI (38.5 kg/m²), and weekly stool frequency (from 2–3 to 9–10 times).
• Clear temporal resolution, tracking symptom onset post-injection and improvement over a three-week period.

Limitations

• Dataset scale is extremely limited, consisting of a single case report (n=1).
• Row count and column-level documentation are unknown; data structure must be inferred from the narrative PDF.
• Data may reflect selection bias inherent to a single, non-randomized case report from figshare.

Provenance

Source

figshare

Collection Method

Clinical case report documented by medical authors.

Freshness

Last updated 2026-05-09 07:55:21